AFMD - Affimed says 86% of patients responded to lymphoma therapy in mid-stage trial
2024-06-12 09:17:41 ET
More on Affimed
- Affimed N.V. 2024 Q1 - Results - Earnings Call Presentation
- Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better
- Affimed N.V. (AFMD) Q4 2023 Earnings Call Transcript
- Affimed gets FDA fast track status for AFM24 for EGFR lung cancer
- Seeking Alpha’s Quant Rating on Affimed